Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 581-592

  Billam, Madhavi ^a   Sobolewski, Michele D ^b   Davidson, Nancy E ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; DNA methyltransferase; Epigenetic; Estrogen receptor; Zebularine

Indexed keywords

CYCLIN D; PROTEIN P21; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CELL LEVEL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPIGENETICS; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYTIDINE; CYTIDINE DEAMINASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; S PHASE; TUMOR STEM CELL ASSAY;

EID: 77950867869     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0420-3     Document Type: Article

References (42)

1. 1. Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1.113. doi: 10.11.26/science.1145720 (Pubitemid 350134889)
2. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116. doi:10.1038/nrc1799
3. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692. doi: 10.1016/j.cell.2007.01.029
4. Momparler RL, Vesely J, Momparler LF, Rivard GE (1979) Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res 39:3822-3827
5. 5. Santi DV, Norment A, Garrett CE (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl. Acad Sci USA 81:69936997. doi: 10.1073/pnas.81.22.6993 (Pubitemid 15216684)
6. Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57-71. doi: 10.1016/0012-1606(78) 90273-7
7. Gabbara S, Bhagwat AS (1995) The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307:87-92
8. Beisler JA (1978) Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 21:204-208. doi:10.1021/jm00200a012
9. Constantinides PG, Jones PA, Gevers W (1977) Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267:364-366. doi:10.1038/267364a0
10. Marquez VE, Liu PS, Kelley JA, Driscoll JS, McCormack JJ (1980) Synthesis of 1, 3-diazepin-2-one nucleosides as transitionstate inhibitors of cytidine deaminase. J Med Chem 23:713-715. doi:10.1021/jm00181a001
11. Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ (1986) Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29:1374-1380. doi:10.1021/jm00158a009
12. Laliberte J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7-11. doi:10.1007/BF00686478
13. Marquez VE, Barchi JJ Jr, Kelley JA et al (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 24:305-318. doi:10.1081/NCN-200059765
14. Hurd PJ, Whitmarsh AJ, Baldwin GS et al (1999) Mechanismbased inhibition of CV-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 286:389-401. doi:10.1006/jmbi.1998. 2491
15. Cheng JC, Matsen CB, Gonzales FA et al (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399-409
16. 16. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF (2007) Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with pl5INK4B demethylation and reexpression. Exp Hematol 35:263-273. doi: 10.1016/j.exphem.2006.10.005 (Pubitemid 46135814)
17. 17. Rao SP, Rechsteiner MP, Berger C, Sigrist JA, Nadal D, Bernasconi M (2007) Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol Cancer 6:6 (Pubitemid 46210991)
18. Cheng JC, Weisenberger DJ, Gonzales FA et al (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270-1278. doi: 1.0.1128/MCB.24.3.1270-1278.2004
19. Cheng JC, Yoo CB, Weisenberger DJ et al (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6:151-158. doi: 10.1016/j.ccr.2004.06. 023
20. 20. Agosten AT, Argani P, Yegnasubramanian S et al (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 280:18302-18310. doi : 10.1074/jbc.M501675200 (Pubitemid 41389076)
21. Hahm HA, Dunn VR, Butash KA et al (2001) Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7:391-399
22. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protocols 1:2315-2319. doi:10,1038/nprot.2006.339
23. Keen JC, Yan L, Mack KM et al (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177-186. doi: 10.1023/A: 1026146524737
24. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen receptornegative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279-2283
25. 25. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19:1740-1751. doi:10.1210/me.2004-0011. (Pubitemid 41007887)
26. 26. Margueron R, Licznar A, Lazennec G, Vignon F, Cavailles V (2003) Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 179:41-53. doi:10.1677/joe.0.1790041 (Pubitemid 37321566)
27. 27. Sheikh MS, Shao ZM, Chen JC, Li XS, Hussain A, Fontana JA (1994) Expression of estrogen receptors in estrogen receptornegative human breast carcinoma cells: modulation of epidermal growth factor-receptor (EGF-R) and transforming growth, factor alpha (TGF alpha) gene expression. J Cell Biochem 54:289-298. doi:10.1002/jcb.240540305 (Pubitemid 24097225)
28. Barchi JJ, Musser S, Marquez VE (1992) The decomposition of 1 -(beta-D-ribofuranosyl)-1, 2-dihydropyrimidin-2-one (zebularine) in alkali - mechanism, and products. J Org Chem 57:536541. doi:10.1021/jo00028a026
29. 29. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32:910-912. doi: 10.1042/BST0320910 (Pubitemid 39655501)
30. 30. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70:121-133. doi:10.1016/j.bcp.2005. 04.010 (Pubitemid 40797876)
31. 31. Pledgie-Tracy A, Sobolewski MD, Davidson NE (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6:1013-1021, doi: 10.1158/ 1535-7163.MCT-06-0494 (Pubitemid 46554571)
32. 32. Tamm I, Wagner M, Schmelz K (2005) Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 84:47-53. doi:10,1007/s00277-005-0013-20 (Pubitemid 44419739)
33. 33. Neureiter D, Zopf S, Leu T et al (2007) Apoptosis, proliferation and differentiation patterns are influenced by zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42:103-116. doi: 10.1080/00365520600874198 (Pubitemid 46033053)
34. 34. Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, Adams PD (2003) Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell 11:341-351. doi: 10.1016/S1097-2765(03)00037-6 (Pubitemid 36293829)
35. Nelson DM, Ye X, Hall C et al (2002) Coupling of DNA synthesis and histone synthesis in S phase independent of cyclin/ cdk2 activity. Mol. Cell Biol 22:7459-7472. doi: 10,1128/MCB, 22.21,7459-7472.2002
36. 36. Milutinovic S, Zhuang Q, Niveleau A, Szyf M (2003) Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem 278:14985-14995. doi: 10.1074/jbc,M213219200 (Pubitemid 36799830)
37. Flotho C, Claus R, Batz C et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. doi:10.1038/leu.2008.397
38. 38. Rhee I, Bachman KE, Park BH et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552-556. doi: 10.1038/416552a (Pubitemid 34288859)
39. 39. Yang X, Ferguson AT, Nass SJ et al (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60:6890-6894 (Pubitemid 32059160)
40. Yoo CB, Chuang JC, Byun HM et al (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res 1:233-240. doi: 10.1158/1940-6207.CAPR-07-0008
41. Eliopoulos N, Cournoyer D, Momparler RL (1998) Drug resistance to 5-aza-2′-deoxycytidine, 2′, 2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol. 42:373-378. doi:10.1007/s002800050832
42. Lemaire M., Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16:301-308. doi: 10.1097/00001813-200503000-00009